The AmpliSeq for Illumina Immune Response Panel is a targeted resequencing research assay for quantitating expression of cancer biomarkers in 395 genes involved in tumor–immune system interactions. Key features include:
The Immune Response Panel is part of an integrated RNA-to-annotated variant solution that includes AmpliSeq for Illumina polymerase chain reaction (PCR)-based library preparation, Illumina sequencing by synthesis (SBS) next-generation sequencing (NGS) technology, and automated analysis.
This panel detects biomarkers associated with different leukocyte subsets, antigen presentation, checkpoint pathways, and tumor progression. The ready-to-use panel saves you the time and effort of identifying targets, designing primers, and optimizing panels.
| Instrument | Recommended Number of Samples | Read Length |
|---|---|---|
| iSeq 100 System | 4 samples per run (assumes 1 million reads per sample) | 2 × 150 bp |
| MiniSeq System | Samples per run: mid output: 8, high output: 24 (assumes 1 million reads per sample) | 2 × 150 bp |
| MiSeq System | Samples per run (by reagent kit version): v2 micro: 4, v2: 15, v3: 24 (assumes 1 million reads per sample) | 2 × 150 bp |
AmpliSeq for Illumina Oncology Panels on the iSeq 100 System
Application Note | PDF< 1 MB
Automated Solutions for AmpliSeq for Illumina Sequencing Panels
Application Note | HTML
Data Sheet | HTML | 7 versions
AmpliSeq for Illumina Immune Response Panel Gene List
product_file | EXCEL< 1 MB
AmpliSeq for Illumina Immune Response Panel Consumables & Equipment Documentation
AmpliSeq for Illumina Immune Response Panel Reference Guide Documentation
AmpliSeq for Illumina Immune Response Panel Documentation
Index Adapters Pooling Guide Documentation
AmpliSeq for Illumina Immune Response Panel Checklist Documentation
Illumina Adapter Sequences Documentation
Custom Protocol Selector
Generates customized, end-to-end instructions
Targeted DNA and RNA research panel investigating variants across 161 genes associated with a range of cancer types.
Targeted DNA and RNA research panel investigating 52 genes with known relevance to solid tumors.
Targeted research panel investigating hotspot regions of 50 genes with known associations to cancer.
Targeted panel that measures expression levels of >20,000 human RefSeq genes.
Targeting 1385 cancer genes for gene expression, variant, and fusion detection studies in many RNA sample types including blood, bone marrow, and formalin-fixed, paraffin-embedded (FFPE) tissue.
Targeted research panel investigating somatic and germline variants in BRCA1 and BRCA2.
